WO2024018365A1 - A probiotic formulation for improving oral health and for prophylaxis of cancer - Google Patents
A probiotic formulation for improving oral health and for prophylaxis of cancer Download PDFInfo
- Publication number
- WO2024018365A1 WO2024018365A1 PCT/IB2023/057280 IB2023057280W WO2024018365A1 WO 2024018365 A1 WO2024018365 A1 WO 2024018365A1 IB 2023057280 W IB2023057280 W IB 2023057280W WO 2024018365 A1 WO2024018365 A1 WO 2024018365A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- lactobacillus
- concentration
- probiotic
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 238000009472 formulation Methods 0.000 title claims abstract description 80
- 239000006041 probiotic Substances 0.000 title claims abstract description 52
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 52
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 45
- 230000036541 health Effects 0.000 title claims abstract description 26
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 title claims description 30
- 201000011510 cancer Diseases 0.000 title claims description 23
- 239000002324 mouth wash Substances 0.000 claims abstract description 18
- 229940051866 mouthwash Drugs 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims abstract description 16
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 13
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 7
- 241001310552 Acetobacter syzygii Species 0.000 claims abstract description 6
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 6
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 6
- 241000186660 Lactobacillus Species 0.000 claims abstract description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 6
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims abstract description 6
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 6
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 6
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 6
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 6
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims abstract description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 6
- 238000005057 refrigeration Methods 0.000 claims abstract description 3
- 241000193749 Bacillus coagulans Species 0.000 claims description 11
- 229940054340 bacillus coagulans Drugs 0.000 claims description 11
- 244000005709 gut microbiome Species 0.000 claims description 10
- 108010001682 Dextranase Proteins 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 235000019143 vitamin K2 Nutrition 0.000 claims description 4
- 239000011728 vitamin K2 Substances 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000008368 mint flavor Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000019621 digestibility Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 5
- 230000036952 cancer formation Effects 0.000 abstract description 5
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 5
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 208000003445 Mouth Neoplasms Diseases 0.000 description 12
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000736262 Microbiota Species 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 241000282941 Rangifer tarandus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000656 anti-yeast Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 244000005702 human microbiome Species 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000190888 Capnocytophaga gingivalis Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000959640 Fusobacterium sp. Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000192033 Peptostreptococcus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- -1 Polyethylene terephthalate Polymers 0.000 description 1
- 241000611831 Prevotella sp. Species 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- a probiotic formulation for improving oral health and for prophylaxis of cancer A probiotic formulation for improving oral health and for prophylaxis of cancer
- the present invention relates to a formulation of probiotic solution as mouth wash for improving oral health, gut health and as prophylaxis for oral cancer. More particularly, the invention relates to a unique mouth wash formulation of probiotic solution comprising beneficial bacteria to optimize the oral health, gut health and to inhibit carcinogenesis.
- Oral cancer also known as mouth cancer refers to cancer of the lining of the lips, mouth, or upper throat. In the mouth, it most commonly starts as a painless white patch, that thickens, develops red patches, an ulcer, and continues to grow.
- oral cancers oral squamous cell carcinoma (OSCC) is the most prevalent and most commonly studied, and it is the most common malignancy of the head and neck worldwide.
- OSCC oral squamous cell carcinoma
- Oral cancer is a multifactorial disease and is caused by the host genetics and various environmental factors.
- the consumption of tobacco, alcohol betel quid chewing, smoking cigarettes, cigars, and pipe and infections with human papillomavirus (HPV) are the known risk factors.
- HPV human papillomavirus
- Oral cancer belongs to a larger group of cancers called head and neck cancers. Most cancers develop in the squamous cells found in mouth, tongue, and lips.
- microbiome About 30 trillion bacterial cells are living in or on every human i.e., is around one bacterium for each cell in the human body. These microorganisms are on the whole known as the microbiome.
- oral microbiome members of the human microbiome are highly associated with a wide variety of cancer types.
- the presence of oral microbiome is associated with risk of distant multiple cancers such as gastrointestinal-esophageal cancer, pancreatic cancer, hepatic cancer, colorectal cancer, gastric cancer, apart from breast cancer and lung cancer.
- Some specific species have been identified that correlate strongly with oral cancer, such as Streptococcus sp., Peptostreptococcus sp., Prevotella sp., Fusobacterium sp., Porphyromonas gingivalis, and Capnocytophaga gingivalis.
- the microbiome may influence the evolution of the disease by directly interacting with the human body and significantly altering the response and toxicity to various forms of cancer therapy.
- the oral cavity and gut are anatomically continuous regions connected through the gastrointestinal (GI) tract. Moreover, both sites are also chemically connected, since saliva and digested food pass through the GI tract. Studies in animals and human have indicated that oral bacteria can translocate to the gut and change its microbiota and possibly immune defense.
- GI gastrointestinal
- Probiotics are made of good live bacteria that naturally live in the human body. Probiotics maintain a healthy balance in the human body by supporting the immune function and controlling inflammation. In addition, probiotics also help the body to digest food, enhance vitamin production, combat bad bacteria and support the cells that line the gut to prevent bad bacteria from entering blood.
- the existing probiotics may reduce the negative bacteria but may harm the positive bacteria in the oral cavity and are detrimental to oral health.
- Some studies and extensive data have suggested a link between excessive use of mouthwash especially alcohol based, and oral cancer.
- the Patent Application CN103798392B entitled “The probiotic food composition and food of alleviating botleneck throat inflammation effect” discloses a kind of probiotic food composition and the food with alleviation bottleneck throat inflammation effect.
- Probiotic food composition of the present invention can be added in various healthy food and health food such as acidified milk, milk sheet etc., can be used for effectively alleviating bottleneck throat inflammation particularly chronic pharyngitis.
- compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life discloses an inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice.
- the compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency -associated cancers.
- the compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation.
- the compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.
- Patent Application US8187590B2 entitled “Probiotic, lactic acidproducing bacteria and uses thereof discloses utilization of species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic -resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen.
- the invention relates to the utilization of therapeutic compounds comprised of lactic acidproducing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.
- the invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria- mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.
- anti-microbial agents e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents
- probiotics possess anti-proliferative or pro- apoptotic activities in gastrointestinal cancers
- probiotic formulation with specific combination of micro-organisms that helps in improving oral health and to prevent carcinogenesis.
- the present invention discloses a formulation of mouthwash solution comprising probiotic for improving oral health and as prophylaxis for oral cancer.
- the formulation of the present invention relates to a formulation of a probiotic alone or in combination of specific beneficial micro-organisms that enhances the oral health, gut health and acts as prophylaxis for cancer.
- the formulation is a probiotic solution as mouthwash to improve the oral and gut health.
- the probiotic formulation comprises any of the probiotic specifies such as Bacillus coagulus Acetobacter syzygii, Lactobacillus salivarius REN, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus.
- Bacillus coagulus Acetobacter syzygii Lactobacillus salivarius REN
- Lactobacillus plantarum Streptococcus thermophilus
- Bifidobacterium longum Bifidobacterium breve
- Bifidobacterium infantis Lactobacillus acidophilus
- Lactobacillus plantarum Lactobacillus casei and Lactobacillus bulgaricus.
- the probiotic formulation comprises Acetobacter syzygii at a concentration of in a range between 20% and 30%, Lactobacillus species comprising Lactobacillus salivarius REN, Lactobacillus plantarum and Bacillus coagulans at a concentration in a range between 25% and 40%, the combination of Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30% and dextranase.
- the formulation also comprises vitamin, sweetener, color and flavor to improve the compatibility of patients.
- the formulation with specific combination is prepared comprising Bacillus coagulans at a concentration of 10 Bn cfu in 5 ml, vitamin K2 at a concentration of 5 mcg, dextranase at a concentration of 10 ppm 30000 u per g, mint flavor, sweetener and color.
- the volume of the solution is made up to 150 ml with distilled water.
- the formulation is effective in modifying the intestinal microbiota composition, enhancing immunity and also exhibits anticancer activity. Bacillus spores are stable at room temperature thus retaining stability. Thus the formulation overcomes the problem of long-term stability during logistics and storage. The formulation also enhances the innate and acquired immunity by promoting the maturation of antigen-presenting cells.
- the formulation is safe, non-toxic, effective in improving gut and intestinal microbiota, and inhibiting carcinogenesis by modifying the microbiota and enhances the protein absorption.
- the formulation is recommended for oral dosage form as mouthwash, mouth spray and chewable formulations such as oral dispersible tablet, a chewable gum, a chewable tablet, a lozenge or any other form compliant to patients.
- FIGURE 1 tabulates the formulation of the probiotic solution according to an embodiment of the invention.
- FIGURE 2 tabulates the formulation of Bacillus coagulans probiotic mouth wash.
- Probiotic refers to live microorganisms promoted that provide health benefits when consumed, generally by improving or restoring the gut flora.
- Microbiome refers to the genome of all the microorganisms, symbiotic and pathogenic, living in and on all vertebrates.
- Carcinogenesis refers to a process of formation of a cancer, whereby normal cells are transformed into cancer cells.
- the present invention disclsoes a formulation of a probiotic with a combination of specific beneficial micro-organisms that enhances the oral health and acts as prophylaxis for cancer.
- the probiotic formulation comprises any of the probiotic specifies such as Bacillus coagulans, Acetobacter syzygii, Lactobacillus salivarius REN, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus.
- Bacillus coagulans such as Bacillus coagulans, Acetobacter syzygii, Lactobacillus salivarius REN, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus.
- the formulation of the present invention is prepared as mouthwash for improved efficacy.
- FIG 1 tabulates the formulation of the probiotic solution according to an embodiment of the invention.
- the probiotic formulation comprises Acetobacter syzygii at a concentration of in a range between 20% and 30%, Lactobacillus species comprising Lactobacillus salivarius REN, Lactobacillus plantarum and Bacillus coagulans at a concentration in a range between 25% and 40%, the combination of Streptococcus thermophilus , Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30% and dextranase.
- the formulation also comprises vitamin, sweetener, flavor and some added and edible colors to enhance the compatibility of the mouthwash solution.
- the vitamin used is generally vitamin K2.
- the probiotic formulation of the present invention comprises the probiotic as alone or in combination with various combinations and is prepared as a solution to be used as mouth wash.
- the formulation is free of any chemical or synthetic ingredients thus reducing the risk of adverse effects.
- Bacteria used in the formulation of the present invention is unique in enhancing the activity and acts in synergism with other bacteria.
- Acidobacter syzygii used in the probiotic formulation is generally isolated from the regional traditional dairy products. Acidobacter syzygii exhibits antiproliferative activity in human oral cancer cell lines. The human oral cancer cells treated with Acidobacter syzygii exhibited cytotoxicity and apoptosis indicating the effect of Acidobacter syzygii- The cytotoxic effect of Acidobacter syzygii is due to the intact secretion metabolites of Acidobacter syzygii on cancerous cells but not in normal cells.
- Lactobacillus species exhibits anticancer effects in cancerous cells. Lactobacillus exhibits anticancer activity by altering the interleukin-2 signaling and reduces the proliferation of cancer cells and inducing cell cycle arrest resulting in apoptosis. Lactobacillus salivarius REN downregulates the expressions of cyclooxygenase-2 (COX-2) in vitro. Lactobacillus plantarum also exhibits cytotoxic activity by downregulating the expression of Mitogen- Activated Protein Kinase (MAPK) and upregulates the expression of Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) signaling pathways in cancer cells.
- MAPK Mitogen- Activated Protein Kinase
- Example 1 The formulation of Bacillus coagulans probiotic mouth wash solution
- the formulation of the present invention is prepared in a different combination of the probiotics to enhance its efficacy in combination with vitamin, flavors and colors as permitted.
- FIG 2 tabulates the formulation of Bacillus coagulans probiotic mouth wash.
- the formulation comprises Bacillus coagulans at a concentration of 10 Bn cfu in 5 ml, vitamin K2 at a concentration of 5 mcg, dextranase at a concentration of 10 ppm 30000 u per g, mint flavor, sweetener and color.
- the volume of the solution is made up to 150 ml with distilled water.
- the formulation is in the form of solution and is stored in Polyethylene terephthalate (PET) bottle.
- PET Polyethylene terephthalate
- the antic arcinogenic activity of probiotics is based on different mechanisms such as modification of the intestinal microbiota composition, metabolic activity of the intestinal microbiota, production of compounds such as short-chain fatty acids and conjugated linoleic acid that exhibits anticarcinogenic activity, inhibition of cell proliferation and induction of apoptosis in cancer cells, influence on other mutagenic and carcinogenic factors, binding and degradation of carcinogenic compounds present in the intestinal lumen, through immunomodulation and improvement of the intestinal barrier.
- the formulation of the present invention is effective in modifying the intestinal microbiota composition, enhancing immunity and also exhibits anticancer activity.
- the formulation also exhibits stability during storage without requiring any additional refrigeration. This is the advantage of the present formulation which makes the Bacillus spores stable at room temperature thus retaining stability.
- the formulation overcomes the problem of long-term stability during logistics and storage.
- the probiotic formulation of the present invention is prepared in the form of “Safe if swallowed” mouthwash probiotic solution comprising a combination of beneficial bacteria that improves oral health and prevents cancer.
- the formulation upon swallowing after oral rinsing reside in the intestine, thus modulating the gut microbiota along with oral microbiota by increasing the number of beneficial microorganisms and counteracting or antagonizing pathogenic microorganisms. Its positive impact on oral health is observed through reduction in caries-causing microorganisms.
- the metabolites of probiotic oral mouthwash exhibit an impact both on oral health and general health by activating and enhancing the immune system.
- the formulation enhances both innate and adaptive immunity by promoting the maturation of antigen-presenting cells and altering the production of both immune activating and anti-inflammatory cytokines and chemokines. In addition, they also reduce intestinal inflammation by regulating cytokines, inhibiting active oxygen, and enhancing phagocytosis.
- the formulation of the present invention aids in digesting the plant proteins including peas, soybeans, rice and reduce the number of proteins that are transported to the colon thus reducing the possibility of proteins being fermented into toxic metabolites by intestinal microbiota.
- the formulation exhibits dual functions firstly enhancing the amino acid bioavailability of plant proteins in the upper intestinal tract and secondly making the microenvironment healthier in colon thus improving the gut health.
- consumption with protein also improves protein absorption and utilization.
- the formulation is not restricted to mouthwash solution it can also be prepared in alternate forms such as a rinse, a strip, a gel, a mouth spray or chewable formulations such as oral dispersible tablet, a chewable gum, a chewable tablet, a lozenge or any other form compliant to patients.
- the formulation of the present invention is swallowable and hence is safe and effective in pediatric population.
- the formulation does not contain chemicals that are harmful to more than 700 species of microbes that live symbiotically in the oral cavity to maintain optimal oral health.
- the formulation of the present invention can also be altered and customized based on the gender of the patient or type of cancer.
- the formulation of probiotic shall be prepared using customized and specific strains of microbes based on the type of cancer to be treated. This specific approach makes the formulation more effective in patients.
- the formulation is also safe to be swallowed in population with lactose intolerance owing to high levels of P-galactosidase activity and lactate dehydrogenase activity, so it enhances the lactose digestibility of the lactose intolerant population.
- the formulation is safe, effective and enhances oral health and is useful as prophylaxis for various cancers.
- the formulation is effective on human gut microbiome.
- the probiotic formulation ensures an optimum balance between the bacteria that are necessary for a normal function of the organism and pathogens thus restoring and maintenance of the homeostasis.
- the formulation also proved to promote nutritional metabolism, maintain intestinal integrity, and reduce oxidative stress and diarrhea.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a mouthwash formulation of probiotic solution comprising beneficial bacteria to optimize the oral health, hut health and for prophylaxis to carcinogenesis. The probiotic formulation comprises any of the probiotic species Bacillus coagulus, Acetobacter syzygii at a concentration of in a range between 20% and 30%, Lactobacillus species comprising Lactobacillus salivarius REN, Lactobacillus plantarum, at a concentration in a range between 25% and 40%, the combination of Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30%. The probiotic formulation of the is prepared in the form of "Safe if swallowed" mouthwash and is stable without the requirement of refrigeration.
Description
A probiotic formulation for improving oral health and for prophylaxis of cancer
Priority Claim:
[0001] This application claims priority from the provisional application numbered 202241002521 filed with Indian Patent Office, Chennai on 17th July 2022 entitled “A probiotic formulation for improving oral health and for prophylaxis of cancer”, the entirety of which is expressly incorporated herein by reference.
Preamble to the description
[0002] The following specification describes the invention and the manner in which it is to be performed:
Description of the invention
Technical field of the invention
[0003] The present invention relates to a formulation of probiotic solution as mouth wash for improving oral health, gut health and as prophylaxis for oral cancer. More particularly, the invention relates to a unique mouth wash formulation of probiotic solution comprising beneficial bacteria to optimize the oral health, gut health and to inhibit carcinogenesis.
Background of the invention
[0004] Cancer, being a second main cause of the death in the world is associated with role of pathogens. Oral cancer also known as mouth cancer refers to cancer of the lining of the lips, mouth, or upper throat. In the mouth, it most commonly starts as a painless white patch, that thickens, develops red patches, an ulcer, and continues to grow. Among oral cancers, oral squamous cell carcinoma (OSCC) is
the most prevalent and most commonly studied, and it is the most common malignancy of the head and neck worldwide.
[0005] Oral cancer is a multifactorial disease and is caused by the host genetics and various environmental factors. In addition, the consumption of tobacco, alcohol betel quid chewing, smoking cigarettes, cigars, and pipe and infections with human papillomavirus (HPV) are the known risk factors. However, it also be a possible etiology that could be attributed to microbes in around 15% of oral cancer patients without any known risk factors.
[0006] Oral cancer belongs to a larger group of cancers called head and neck cancers. Most cancers develop in the squamous cells found in mouth, tongue, and lips.
[0007] About 30 trillion bacterial cells are living in or on every human i.e., is around one bacterium for each cell in the human body. These microorganisms are on the whole known as the microbiome. The increased interest in the role that the human microbiome plays in human health, many studies have linked changes in microbial communities to systemic conditions such as allergies, diabetes, inflammatory bowel disease, and atherosclerosis. Among the systemic conditions influenced by the microbiome, cancer has not been an exception.
[0008] It is observed that members of the human microbiome are highly associated with a wide variety of cancer types. The presence of oral microbiome is associated with risk of distant multiple cancers such as gastrointestinal-esophageal cancer, pancreatic cancer, hepatic cancer, colorectal cancer, gastric cancer, apart from breast cancer and lung cancer. Some specific species have been identified that correlate strongly with oral cancer, such as Streptococcus sp., Peptostreptococcus sp., Prevotella sp., Fusobacterium sp., Porphyromonas gingivalis, and Capnocytophaga gingivalis. It is observed that the oral periopathogens namely Fusobacterium nucleatum and Porphyromonas gingivalis play an important role in the development of colorectal and pancreatic cancer.
[0009] Similarly, Tannerella forsythia is associated with higher risk of esophageal adenocarcinoma and depletion of Neisseria and Streptococcus pneumoniae is associated with lower risk of esophageal adenocarcinoma. The abundance of P. gingivalis is associated with higher risk of esophageal squamous cell carcinoma.
[0010] The microbiome may influence the evolution of the disease by directly interacting with the human body and significantly altering the response and toxicity to various forms of cancer therapy. Some studies have shown an association of certain phylogenetic groups with the immunotherapy treatment outcomes of certain tumors. However, in contrast, it has also been a resurgence in interest on the potential use of bacteria to cure cancer.
[0011] There are different mechanisms explained regarding the role of microbiota in the pathogenesis of cancer. Firstly, bacterial stimulation of chronic inflammation and the inflammatory mediators produced in this process facilitate cell proliferation, mutagenesis, oncogene activation, and angiogenesis. The second mechanism attributed to bacteria that influence the pathogenesis of cancers by affecting cell proliferation is the activation of NF-KB and inhibition of cellular apoptosis. Thirdly, bacteria produce certain substances that act in a carcinogenic manner.
[0012] There is a wide inter-individual diversity in microbial colonization in the oral cavity. This micro -environmental variability connected to the oral microbial flora is likely to modify tumor cell genotype and phenotype. This leads to heterogeneity in the tumor cells.
[0013] The oral cavity and gut are anatomically continuous regions connected through the gastrointestinal (GI) tract. Moreover, both sites are also chemically connected, since saliva and digested food pass through the GI tract. Studies in animals and human have indicated that oral bacteria can translocate to the gut and change its microbiota and possibly immune defense.
[0014] Probiotics are made of good live bacteria that naturally live in the human body. Probiotics maintain a healthy balance in the human body by supporting the immune function and controlling inflammation. In addition, probiotics also help the
body to digest food, enhance vitamin production, combat bad bacteria and support the cells that line the gut to prevent bad bacteria from entering blood.
[0015] The existing probiotics may reduce the negative bacteria but may harm the positive bacteria in the oral cavity and are detrimental to oral health. Some studies and extensive data have suggested a link between excessive use of mouthwash especially alcohol based, and oral cancer.
[0016] The Patent Application CN103798392B entitled “The probiotic food composition and food of alleviating botleneck throat inflammation effect” discloses a kind of probiotic food composition and the food with alleviation bottleneck throat inflammation effect. Probiotic food composition of the present invention can be added in various healthy food and health food such as acidified milk, milk sheet etc., can be used for effectively alleviating bottleneck throat inflammation particularly chronic pharyngitis.
[0017] The Patent Application US2016000841A1 entitled “Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life ” discloses an inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. The compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency -associated cancers. The compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. The compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.
[0018] The Patent Application US8187590B2 entitled “Probiotic, lactic acidproducing bacteria and uses thereof discloses utilization of species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic -resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of
the colonization of the antibiotic-resistant pathogen. In addition, the invention relates to the utilization of therapeutic compounds comprised of lactic acidproducing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria- mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.
[0019] Even though it is known that probiotics possess anti-proliferative or pro- apoptotic activities in gastrointestinal cancers there are probiotic formulation with specific combination of micro-organisms that helps in improving oral health and to prevent carcinogenesis.
[0020] Hence, there is a need for a formulation of probiotic with combination of specific bacteria to combat cancer and provide oral health benefits to human.
Summary of the invention
[0021] In order to overcome the drawbacks of the state of art, the present invention discloses a formulation of mouthwash solution comprising probiotic for improving oral health and as prophylaxis for oral cancer.
[0022] The formulation of the present invention relates to a formulation of a probiotic alone or in combination of specific beneficial micro-organisms that enhances the oral health, gut health and acts as prophylaxis for cancer. The formulation is a probiotic solution as mouthwash to improve the oral and gut health. The probiotic formulation comprises any of the probiotic specifies such as Bacillus coagulus Acetobacter syzygii, Lactobacillus salivarius REN, Lactobacillus
plantarum, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus.
[0023] More specifically, the probiotic formulation comprises Acetobacter syzygii at a concentration of in a range between 20% and 30%, Lactobacillus species comprising Lactobacillus salivarius REN, Lactobacillus plantarum and Bacillus coagulans at a concentration in a range between 25% and 40%, the combination of Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30% and dextranase.
[0024] In addition, the formulation also comprises vitamin, sweetener, color and flavor to improve the compatibility of patients.
[0025] Further, the formulation with specific combination is prepared comprising Bacillus coagulans at a concentration of 10 Bn cfu in 5 ml, vitamin K2 at a concentration of 5 mcg, dextranase at a concentration of 10 ppm 30000 u per g, mint flavor, sweetener and color. The volume of the solution is made up to 150 ml with distilled water.
[0026] The formulation is effective in modifying the intestinal microbiota composition, enhancing immunity and also exhibits anticancer activity. Bacillus spores are stable at room temperature thus retaining stability. Thus the formulation overcomes the problem of long-term stability during logistics and storage. The formulation also enhances the innate and acquired immunity by promoting the maturation of antigen-presenting cells.
[0027] The formulation is safe, non-toxic, effective in improving gut and intestinal microbiota, and inhibiting carcinogenesis by modifying the microbiota and enhances the protein absorption. The formulation is recommended for oral dosage form as mouthwash, mouth spray and chewable formulations such as oral
dispersible tablet, a chewable gum, a chewable tablet, a lozenge or any other form compliant to patients.
Brief description of the drawings
[0028] The foregoing and other features of embodiments will become more apparent from the following detailed description of embodiments when read in conjunction with the accompanying drawings. In the drawings, like reference numerals refer to like elements.
[0029] FIGURE 1 tabulates the formulation of the probiotic solution according to an embodiment of the invention.
[0030] FIGURE 2 tabulates the formulation of Bacillus coagulans probiotic mouth wash.
Detailed description of the invention
[0031] In order to more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms, which are used in the following written description.
[0032] The term “Probiotic” refers to live microorganisms promoted that provide health benefits when consumed, generally by improving or restoring the gut flora.
[0033] The term “Microbiome” refers to the genome of all the microorganisms, symbiotic and pathogenic, living in and on all vertebrates.
[0034] The term “Carcinogenesis” refers to a process of formation of a cancer, whereby normal cells are transformed into cancer cells.
[0035] The present invention disclsoes a formulation of a probiotic with a combination of specific beneficial micro-organisms that enhances the oral health and acts as prophylaxis for cancer.
[0036] The probiotic formulation comprises any of the probiotic specifies such as Bacillus coagulans, Acetobacter syzygii, Lactobacillus salivarius REN, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus.
[0037] The formulation of the present invention is prepared as mouthwash for improved efficacy.
[0038] FIG 1 tabulates the formulation of the probiotic solution according to an embodiment of the invention. The probiotic formulation comprises Acetobacter syzygii at a concentration of in a range between 20% and 30%, Lactobacillus species comprising Lactobacillus salivarius REN, Lactobacillus plantarum and Bacillus coagulans at a concentration in a range between 25% and 40%, the combination of Streptococcus thermophilus , Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30% and dextranase.
[0039] The formulation also comprises vitamin, sweetener, flavor and some added and edible colors to enhance the compatibility of the mouthwash solution. The vitamin used is generally vitamin K2.
[0040] The probiotic formulation of the present invention comprises the probiotic as alone or in combination with various combinations and is prepared as a solution to be used as mouth wash. The formulation is free of any chemical or synthetic ingredients thus reducing the risk of adverse effects.
[0041] Bacteria used in the formulation of the present invention is unique in enhancing the activity and acts in synergism with other bacteria.
[0042] Acidobacter syzygii, used in the probiotic formulation is generally isolated from the regional traditional dairy products. Acidobacter syzygii exhibits antiproliferative activity in human oral cancer cell lines. The human oral cancer cells treated with Acidobacter syzygii exhibited cytotoxicity and apoptosis indicating the effect of Acidobacter syzygii- The cytotoxic effect of Acidobacter syzygii is due to the intact secretion metabolites of Acidobacter syzygii on cancerous cells but not in normal cells.
[0043] Lactobacillus species exhibits anticancer effects in cancerous cells. Lactobacillus exhibits anticancer activity by altering the interleukin-2 signaling and reduces the proliferation of cancer cells and inducing cell cycle arrest resulting in apoptosis. Lactobacillus salivarius REN downregulates the expressions of cyclooxygenase-2 (COX-2) in vitro. Lactobacillus plantarum also exhibits cytotoxic activity by downregulating the expression of Mitogen- Activated Protein Kinase (MAPK) and upregulates the expression of Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) signaling pathways in cancer cells.
[0044] The following examples are offered to illustrate various aspects of the invention. However, the examples are not intended to limit or define the scope of the invention in any manner.
Example 1: The formulation of Bacillus coagulans probiotic mouth wash solution
[0045] The formulation of the present invention is prepared in a different combination of the probiotics to enhance its efficacy in combination with vitamin, flavors and colors as permitted.
[0046] FIG 2 tabulates the formulation of Bacillus coagulans probiotic mouth wash. The formulation comprises Bacillus coagulans at a concentration of 10 Bn
cfu in 5 ml, vitamin K2 at a concentration of 5 mcg, dextranase at a concentration of 10 ppm 30000 u per g, mint flavor, sweetener and color. The volume of the solution is made up to 150 ml with distilled water. The formulation is in the form of solution and is stored in Polyethylene terephthalate (PET) bottle.
[0047] The antic arcinogenic activity of probiotics is based on different mechanisms such as modification of the intestinal microbiota composition, metabolic activity of the intestinal microbiota, production of compounds such as short-chain fatty acids and conjugated linoleic acid that exhibits anticarcinogenic activity, inhibition of cell proliferation and induction of apoptosis in cancer cells, influence on other mutagenic and carcinogenic factors, binding and degradation of carcinogenic compounds present in the intestinal lumen, through immunomodulation and improvement of the intestinal barrier.
[0048] The formulation of the present invention is effective in modifying the intestinal microbiota composition, enhancing immunity and also exhibits anticancer activity. In addition, the formulation also exhibits stability during storage without requiring any additional refrigeration. This is the advantage of the present formulation which makes the Bacillus spores stable at room temperature thus retaining stability. Thus the formulation overcomes the problem of long-term stability during logistics and storage.
[0049] The probiotic formulation of the present invention is prepared in the form of “Safe if swallowed” mouthwash probiotic solution comprising a combination of beneficial bacteria that improves oral health and prevents cancer. In addition to safety, the formulation upon swallowing after oral rinsing, reside in the intestine, thus modulating the gut microbiota along with oral microbiota by increasing the number of beneficial microorganisms and counteracting or antagonizing pathogenic microorganisms. Its positive impact on oral health is observed through reduction in caries-causing microorganisms.
[0050] The metabolites of probiotic oral mouthwash exhibit an impact both on oral health and general health by activating and enhancing the immune system. The
formulation enhances both innate and adaptive immunity by promoting the maturation of antigen-presenting cells and altering the production of both immune activating and anti-inflammatory cytokines and chemokines. In addition, they also reduce intestinal inflammation by regulating cytokines, inhibiting active oxygen, and enhancing phagocytosis.
[0051] Upon swallowing, the formulation of the present invention aids in digesting the plant proteins including peas, soybeans, rice and reduce the number of proteins that are transported to the colon thus reducing the possibility of proteins being fermented into toxic metabolites by intestinal microbiota. As a result, the formulation exhibits dual functions firstly enhancing the amino acid bioavailability of plant proteins in the upper intestinal tract and secondly making the microenvironment healthier in colon thus improving the gut health. Moreover, consumption with protein also improves protein absorption and utilization.
[0052] The formulation is not restricted to mouthwash solution it can also be prepared in alternate forms such as a rinse, a strip, a gel, a mouth spray or chewable formulations such as oral dispersible tablet, a chewable gum, a chewable tablet, a lozenge or any other form compliant to patients.
[0053] The formulation of the present invention is swallowable and hence is safe and effective in pediatric population. The formulation does not contain chemicals that are harmful to more than 700 species of microbes that live symbiotically in the oral cavity to maintain optimal oral health.
[0054] The formulation of the present invention can also be altered and customized based on the gender of the patient or type of cancer. The formulation of probiotic shall be prepared using customized and specific strains of microbes based on the type of cancer to be treated. This specific approach makes the formulation more effective in patients.
[0055] It is proved that the formulation is also safe to be swallowed in population with lactose intolerance owing to high levels of P-galactosidase activity and lactate dehydrogenase activity, so it enhances the lactose digestibility of the lactose intolerant population.
[0056] The formulation is safe, effective and enhances oral health and is useful as prophylaxis for various cancers. The formulation is effective on human gut microbiome. The probiotic formulation ensures an optimum balance between the bacteria that are necessary for a normal function of the organism and pathogens thus restoring and maintenance of the homeostasis. The formulation also proved to promote nutritional metabolism, maintain intestinal integrity, and reduce oxidative stress and diarrhea.
Claims
1. A formulation of probiotic solution, the formulation comprising at least one probiotic species selected from: a. Bacillus coagulans, Lactobacillus species comprising Lactobacillus salivarius REN or Lactobacillus plantarum at a concentration in a range between 25% and 40%; b. Acetobacter syzygii at a concentration of in a range between 20% and 30%; and c. the combination of Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus bulgaricus at a concentration in a range between 20% to 30%; wherein the probiotic is used in a carrier dextranase at a concentration in a range between 1% to 2% to improve the oral health, gut health and for prophylaxis of cancer.
2. The formulation of Claim 1 , wherein the formulation additionally comprises vitamin, sweetener, color and flavor to enhance the compatibility of the formulation.
3. The formulation of Claim 1, wherein the formulation is used for oral administration as “Safe If Swallowed”.
4. The formulation of Claim 1, wherein the formulation is safe, enhances immunity, exhibits anticancer activity by modifying intestinal microbiota.
5. The formulation of Claim 1, wherein the formulation specifically comprises Bacillus coagulans at a concentration of 10 Bn cfu in 5 ml, vitamin K2 at a
concentration of 5 mcg, dextranase at a concentration of 10 ppm 30000 u per g, mint flavor, sweetener and color. The formulation of Claim 1, wherein the formulation exhibits stability at room temperature without the requirement of refrigeration. The formulation of Claim 1, wherein the formulation improves lactose digestibility. The formulation of Claim 1, wherein the formulation oral dosage form is selected from a group comprising a mouthwash, a rinse, a strip, a gel, a mouth spray or chewable formulations such as oral dispersible tablet, a chewable gum, a chewable tablet, a lozenge or any other form compliant to patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241002521 | 2022-07-17 | ||
IN202241002521 | 2022-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024018365A1 true WO2024018365A1 (en) | 2024-01-25 |
Family
ID=89617280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/057280 WO2024018365A1 (en) | 2022-07-17 | 2023-07-17 | A probiotic formulation for improving oral health and for prophylaxis of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024018365A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200376048A1 (en) * | 2017-11-28 | 2020-12-03 | NUTRAVIS S.r.l. | Composition for the treatment of dysbiosis of the intestinal microbiota |
-
2023
- 2023-07-17 WO PCT/IB2023/057280 patent/WO2024018365A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200376048A1 (en) * | 2017-11-28 | 2020-12-03 | NUTRAVIS S.r.l. | Composition for the treatment of dysbiosis of the intestinal microbiota |
Non-Patent Citations (1)
Title |
---|
KUMAR SS: "Can probiotics stop oral cancer progression?", EVIDENCE-BASED DENTISTRY, vol. 23, no. 1, 25 March 2022 (2022-03-25), pages 22 - 23, XP037766778, DOI: 10.1038/s41432-022-0246-y * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bolognani et al. | Effect of lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats | |
CN110051003A (en) | A kind of compound probiotic composition and its application | |
JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
MX2011006488A (en) | Compositions and methods for improved oral health. | |
KR101287126B1 (en) | Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria | |
JP2005537791A (en) | Probiotic bacteria: Lactobacillus fermentum | |
CZ20014220A3 (en) | Combination of lactic acid bacteria and use thereof for prophylaxis and/or therapy of infections or inflammatory states | |
CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
US11274275B2 (en) | Lactobacillus paracasei ET-22 and use thereof | |
JP2016513631A (en) | Lactobacillus plantarum NCC2936 preparation and oral health | |
US20220110986A1 (en) | Strains, composition and method of use | |
JP6285687B2 (en) | Oral disease preventive agent | |
US7863033B2 (en) | Lactobacillus living body activating Lactobacillus preparation and preventive or therapeutic agent for living body infection | |
KR20140026326A (en) | Compositions and methods for augmenting kidney function | |
US20120039860A1 (en) | Compositions and methods for improved oral health | |
CN1708316A (en) | Method for inhibiting yeast growth | |
KR101518445B1 (en) | Intestine immunomodulator | |
WO2024018365A1 (en) | A probiotic formulation for improving oral health and for prophylaxis of cancer | |
KR102491640B1 (en) | Weissella cibaria strain for suppressing dental caries inducing bacteria and use thereof | |
Bharti et al. | Health benefits of probiotic bacteria as nutraceuticals | |
JP6543614B2 (en) | Retinoic acid producing agent | |
KR20090130136A (en) | Eradicating agent for helicobacter pylori | |
Deshpande et al. | Probiotic Bacteriotherapy and Its Oral Health Perspective | |
Pavithra et al. | Probiotics–A Miracle in Periodontal Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23842528 Country of ref document: EP Kind code of ref document: A1 |